WeTrials
Active, not recruiting

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

What is this study?

This early-stage clinical trial is testing a new medication called OKI-219, both by itself and combined with other cancer drugs. The goal is to see how well and safely this treatment works for people with advanced solid tumors or advanced breast cancer that have a specific gene change.

Who can participate?

This study is for adults with advanced solid tumors or breast cancer who have a specific genetic change called PI3K in their tumor or blood. Participants must also be well enough to carry out daily activities and have properly functioning major organs.

What will happen?

Participants will receive the study medication until their disease gets worse or side effects become too strong. Depending on the study part, they may take OKI-219 alone or alongside other approved and experimental cancer therapies.

Where and when?

This study is currently active but not recruiting new participants at locations in California, United States. Participants will receive regular check-ups from the medical team to monitor their health and response to treatment.

Key Points
  • 1Tests a new targeted medication called OKI-219 for advanced cancers.
  • 2Looks at safety and effectiveness when used alone or with other drugs.
  • 3Requires a specific gene change in the tumor to qualify.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced CancerBreast CancerAdvanced Solid TumorsPI3K Gene Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.